Cardiology

AHA 2023: An intensive 3-year treatment targeting SPB <120 mm Hg resulted in 39% lower CV mortality than standard treatment in patients with HTN at high risk of CVD.

Ndumele chairs the American Heart Association committee that characterized the syndrome and wrote the statement of evidence for its assessment and management.

Which hypertension treatment options should be used as first-line therapy in patients with obesity? A clinician's answer and explanation, here.

AHA 2023: Semaglutide 2.4 mg reduced the risk of serious cardiovascular events by 20% in patients with obesity and overweight with established CVD but without diabetes, according to full SELECT trialresults.

President of the Alabama Obesity Society, Dr Jonathan Parker, discusses obesity as a risk factor for hypertension.

Your daily dose of the clinical news you may have missed.

Only about 30% of more than 3000 adults surveyed in new poll reported talking to their clinician about the adverse effects OTC pain medications can have on blood pressure.

Uptitration of renin-angiotensin-aldosterone system inhibitors was less successful in women with acute heart failure, and particularly those with heart failure with reduced ejection fraction.

Your daily dose of the clinical news you may have missed.

President of the Alabama Obesity Society, Dr Jonathan Parker, provides an in-depth overview of the association between obesity and hypertension.

A new paradigm for reducing CV morbidity and mortality provides a comprehensive approach to comorbid metabolic disease including early detection and treatment.

A novel study strongly suggests that pre-pregnancy obesity rather than associated adverse pregnancy outcomes is the "culprit" in postpartum heart disease.

Semaglutide treatment reduced weight and was associated with greater, more consistent improvements in HFpEF than other recently studied drug classes.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The prevalence of cardiac, renal, and metabolic conditions has significantly increased over 20 years and so has the number of US adults who have all 3.

An e-health lifestyle walking intervention partially supported by remote coaching led to significant improvement in BP in older adults as well as a desire to keep walking.

Etripamil 70 mg nasal spray restored heart rate within 30 minutes in approximately 60% of PSVT episodes, report authors of new study.

The 2022 AAFP Clinical Practice Guideline on hypertension treatment in adults is the subject matter for this 10-question topline quiz that is also a good source of review.

Pivotal cardiovascular outcome trials that evaluated cardiorenal benefits of the newer classes were not designed to consider racial/ethnic variations, researchers state.

The biosimilar to the GLP-1 mimetic Victoza proved noninferior for reduction of HbA1c and had similar positive effects on body weight, lipids, and blood pressure.

Empagliflozin is approved to lower the risk of sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with CKD at risk of progression.

Your daily dose of the clinical news you may have missed.